Statins – HMG-CoA Reductase Inhibitors
High cholesterol is a significant risk factor for cardiovascular disease (CVD) and specifically for coronary heart disease (CHD).
Cardiovascular disease is the leading cause of death in the U.S. In fact, it kills more Americans each year than all cancers combined. Approximately 17% of all national healthcare spending focuses on this disease alone.
By 2030, approximately 40% of the U.S. population is expected to have some form of CVD. As a result, direct medical costs for CVD in the U.S. are expected to triple from $273 billion currently to $818 billion in 2030. Indirect costs, due to lost productivity, are projected to increase by approximately 60% in the same period, from $172 billion to $276 billion. Overall, the total costs of CVD will more than double over the next 20 years, to well over a trillion dollars.